Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ®…
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…
Boise, ID, April 03, 2026 (GLOBE NEWSWIRE) -- This release is based on information provided by Blue Heron Health News…
Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness…
HONG KONG, March 12, 2026 /PRNewswire/ -- Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known…
New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through…
New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- This article contains affiliate links. If a purchase is made through…
A study published in Science reveals that a healthy gut microbiota can enhance the efficacy of immunotherapy used to treat…
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If…
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE…